The National Cancer Society Malaysia (NCSM) leads HPV vaccine coverage recovery through public-private-NGO collaboration, addressing disruptions caused by COVID-19. Their “Leaving No One Behind” program targets underserved groups, including rural populations, refugees, and out-of-school youth. Implementation combines health education, localized outreach, and strong community partnerships to combat hesitancy and improve access. Future plans include expanding […]
Format: Presentation
Country experiences on delivery strategies; Malaysia
Malaysia introduced HPV vaccination in 2010 for 13‑year‑old girls as a cancer prevention strategy, later expanding to catch‑up cohorts. The program, delivered mainly through school health services, achieved high coverage due to strong Ministry of Education collaboration, parental trust, and integration into the National Immunization Program. Policy shifts moved from three‑ to single‑dose schedules and […]
Country experiences on delivery strategies; Myanmar EPI
Myanmar introduced HPV vaccination in 2020 targeting 9-year-old girls but faced program interruptions in 2021–2022 due to instability and supply shortages. In 2023, the program resumed with a catch-up campaign, shifting from a two-dose to a single-dose schedule aligned with WHO recommendations. Delivery combined school-based and community approaches, supported by the Vaccine Management Information System […]
Singapore’s experience on integrated HPV vaccine delivery
Singapore’s HPV vaccination program integrates school-based delivery for 13-year-old girls and community-based services for women aged 18–26. Initially challenged by low awareness and uptake, interventions included adding HPV vaccines to the national schedule, subsidizing costs through CHAS clinics, and implementing targeted outreach such as letters and SMS reminders to encourage appointments. A life-course approach links […]
Conducting out-of-school girl assessment
The presentation reviewed Cambodia’s progress in assessing and vaccinating out‑of‑school (OOS) girls against HPV. While an official OOS assessment has been delayed, CHAI and NIP estimate numbers using census, school enrollment, and community‑level data with support from local authorities. Key challenges include limited denominators, underused data sources, weak coordination, mobile populations, and budget constraints. High […]
Gavi transition and MICs countries pricing
The UNICEF presentation provided an overview of the global HPV vaccine market, highlighting ongoing supply constraints since 2017 and expected stabilization by 2026. It detailed the five WHO-prequalified vaccines available for procurement, including products from GSK, Merck, Innovax, and the newly added Yuxi Zerun. The session reviewed long-term agreements (LTAs) for both Gavi-supported and middle-income […]
HPV vaccine cost and procurement – transitioning out of Gavi support and self-procurement
The Indonesian experience in HPV vaccine procurement highlights the transition from Gavi support to full self-financing within the national immunization program. Facing high cervical cancer incidence, the country initiated phased rollouts since 2016, progressing to nationwide coverage in 2022. Post-Gavi strategies include technology transfer to Biofarma for local vaccine production and cost reduction. Key challenges […]
Accelerated Gavi transitioning experience and HPV vaccine procurement experience
Lao PDR is undergoing a phased transition from Gavi-supported vaccine financing toward full self-financing by 2025, with projected co-financing obligations steadily increasing. HPV vaccination, introduced in 2020 and procured through UNICEF, targets 10-year-old girls with a single-dose schedule, requiring fewer than 100,000 doses annually at an estimated cost of USD 500,000. The country has consistently […]
Considerations for HPV Vaccine product choice
The WHO presentation reviewed the global status of HPV vaccine introduction, noting that 74% of countries have adopted HPV vaccination programs with increasing coverage driven by major introductions in Asia and Africa. It highlighted the 2022 recommendation for a single-dose schedule, now adopted by 58 countries, including high-income nations. Recent evidence supports the inclusion of […]
Single-dose scientific evidence data and implementation progress
The session reviewed global evidence underpinning the WHO’s 2022 recommendation for single-dose HPV vaccination. Data from pivotal trials in Costa Rica, India, and Kenya demonstrated sustained efficacy exceeding 80–90% against HPV 16/18 infection for over a decade. Immunogenicity studies confirmed durable antibody responses comparable to multi-dose schedules, with similar outcomes in boys and girls. Population-level […]